Stocks Health care CRBU
NASDAQ · Health careCaribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. brought in $9.4M of revenue over the twelve months to September 30, 2026, up 1.6% from a year earlier. It posted a net loss of $102.5M. In fiscal 2025 capital spending exceeded operating cash flow by $112.4M. At September 30, 2026 it held $26.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Caribou Biosciences, Inc.
- Net worth
- Caribou Biosciences, Inc. has a market value (market cap) of $42.6M at the latest share price, and shareholders' equity of $76.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $11.2M (+11.7% year on year), with a net loss of $148.1M. Over the 12 months to September 30, 2026: revenue $9.4M, net loss $102.5M.
- Cash flow
- In fiscal 2025 operations used $111M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Caribou Biosciences, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Caribou Biosciences, Inc. does
Caribou Biosciences, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRBU.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $11.2M | -$148.1M | -$1.59 | -$112.4M |
| 2024 | $10M | -$149.1M | -$1.65 | -$143.1M |
| 2023 | $34.5M | -$102.1M | -$1.38 | -$104.9M |
| 2022 | $13.9M | -$99.4M | -$1.64 | -$97.4M |
| 2021 | $9.6M | -$66.9M | -$2.11 | -$34.6M |
| 2021 | $12.4M | -$34.3M | -$4.01 | -$33.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CRBU ranks in Health care
Latest SEC filings
What Caribou Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 27% to $1.6M versus the same quarter last year; diluted EPS -$0.25 versus -$0.30.
- November 5, 2026
- October 6, 2026Executive or director change8-KCaribou Biosciences is exploring strategic alternatives, discontinuing its CAR-T clinical programs, and cutting its workforce.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 44% to $1.5M versus the same quarter last year; diluted EPS -$0.24 versus -$0.58.
- August 13, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 18, 2026
- June 11, 2026
- June 5, 2026Additional proxy material DEFA14A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 1.9% to $2.4M versus the same quarter last year; diluted EPS -$0.26 versus -$0.43.
Insider trades
What the people running Caribou Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| February 25, 2026 | Kelly Timothy PChief Technology Officer | Sold | 6,228 | $12K |
| February 24, 2026 | Mcclung Barbara GChief Legal Officer | Soldpre-planned (10b5-1) | 6,938 | $13.6K |
| February 24, 2026 | Kelly Timothy PChief Technology Officer | Sold | 3,147 | $6.2K |
| February 24, 2026 | Khan Ruhi AhmadChief Business Officer | Soldpre-planned (10b5-1) | 6,938 | $13.6K |
| February 24, 2026 | Albertson Tina M.Chief Medical Officer | Soldpre-planned (10b5-1) | 1,066 | $2.1K |
| February 20, 2026 | Mcclung Barbara GChief Legal Officer | Received as pay | 45,000 | - |
| February 20, 2026 | Kelly Timothy PChief Technology Officer | Received as pay | 45,000 | - |
| February 20, 2026 | Khan Ruhi AhmadChief Business Officer | Received as pay | 45,000 | - |
Who owns CRBU
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bank of America Corp13G, passive | 5.6% | November 14, 2024 |
| Rachel E. Haurwitz13D, may seek influence with 2 related filers | 5% | April 25, 2025 |
Largest institutional holders
Insiders
6 insiders reported holding 1,247,720 shares in total, about $496.1K at the last price.
| Holder | Shares |
|---|---|
| Mcclung Barbara GChief Legal Officer | 481,564 |
| Haurwitz Rachel E.President and CEO, Director | 447,150 |
| Khan Ruhi AhmadChief Business Officer | 104,998 |
| Kelly Timothy PChief Technology Officer | 73,125 |
| Ryali SriramChief Financial Officer | 72,360 |
| Albertson Tina M.Chief Medical Officer | 68,523 |
Questions about CRBU
What does Caribou Biosciences, Inc. do?
Caribou Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as CRBU. Its shares trade on NASDAQ under the ticker CRBU.
What is Caribou Biosciences, Inc.'s net worth?
Caribou Biosciences, Inc. has a market value (market cap) of $42.6M at the latest share price, and shareholders' equity of $76.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Caribou Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $102.5M on revenue of $9.4M.
How much revenue does Caribou Biosciences, Inc. make?
Over the twelve months to September 30, 2026 Caribou Biosciences, Inc. reported revenue of $9.4M. That is 1.6% more than a year earlier.
When did Caribou Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Caribou Biosciences, Inc.'s next earnings report?
Caribou Biosciences, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CRBU with
Follow CRBU
Get an email when Caribou Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Caribou Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.